Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma

Bone Marrow Transplantation volume 43, pages 417–422 (2009)Cite this article

Abstract

Therapeutic options for patients with multiple myeloma whose disease has relapsed after a prior auto-SCT include novel biologic therapies, traditional chemotherapy or a second transplant, with no clear standard of care. Few published studies address the safety and efficacy of a second auto-SCT for relapsed disease. We reviewed the Abramson Cancer Center experience with salvage auto-SCT for relapsed multiple myeloma. Forty-one patients had received a salvage auto-SCT at our institution; the median time between transplants was 37 months (range 3–91). The overall response rate in assessable patients was 55%, and treatment-related mortality was 7%. With a median follow-up time of 15 months, the median PFS was 8.5 months and the median overall survival (OS) was 20.7 months. In a multivariate analysis of OS, independent prognostic factors were ⩾5 prior lines of therapy and time to progression after initial auto-SCT of ⩽12 months. We conclude that in well-selected patients, salvage auto-SCT is safe and effective for relapsed myeloma.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495–2502.

    Article  CAS  Google Scholar 

  2. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883.

    Article  CAS  Google Scholar 

  3. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000; 95: 7–11.

    CAS  PubMed  Google Scholar 

  4. Palumbo A, Triolo S, Argentino C, Bringhen S, Dominietto A, Rus C et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999; 94: 1248–1253.

    CAS  PubMed  Google Scholar 

  5. Mehta J . One or two autografts for myeloma? Blood 2008; 111: 3899–3900.

    Article  CAS  Google Scholar 

  6. Reece DE . Management of multiple myeloma: the changing landscape. Blood Rev 2007; 21: 301–314.

    Article  CAS  Google Scholar 

  7. Mikhael JR, Zadeh S, Samiee S . Second autologous stem cell transplant (ASCT) as salvage therapy in patients with relased multiple myeloma: Improved outcomes in patients with longer disease free interval after first ASCT. Blood 2007; 110: (abstract 946).

  8. Simpson L, Verma R, Kumar S . Outcome after second stem cell transplantation for relapsed multiple myeloma. J Clin Oncol 2007; 25: (abstract 8118).

  9. Mehta J, Singhal S . High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years. Bone Marrow Transplant 2007; 40: 1101–1114.

    Article  CAS  Google Scholar 

  10. Abdelkefi A, Ladeb S, Ben Othman T . Timing of second autologous transplantations in multiple myeloma: Results of a multicenter sequential randomized clinical trial. Blood 2006; 108: (abstract 59).

  11. Qazilbash MH, Saliba R, De Lima M, Hosing C, Couriel D, Aleman A et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 2006; 106: 1084–1089.

    Article  Google Scholar 

  12. Alvares CL, Davies FE, Horton C, Patel G, Powles R, Morgan GJ . The role of second autografts in the management of myeloma at first relapse. Haematologica 2006; 91: 141–142.

    PubMed  Google Scholar 

  13. Lee CK, Barlogie B, Fassas A . Third autotransplant for the management of 98 patients among 1358 who had received prior tandem autotransplants: Benefit apparent when 2nd to 3rd transplant interval exceeds 3 years. Blood 2004; 104: (abstract 540).

  14. Mehta J, Tricot G, Jagannath S, Ayers D, Singhal S, Siegel D et al. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant 1998; 21: 887–892.

    Article  CAS  Google Scholar 

  15. Tricot G, Jagannath S, Vesole DH, Crowley J, Barlogie B . Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant 1995; 16: 7–11.

    CAS  PubMed  Google Scholar 

  16. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.

    Article  CAS  Google Scholar 

  17. Kumar S, Mahmood ST, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK et al. Impact of early relapse after auto-SCT for multiple myeloma. Bone Marrow Transplant 2008; 42: 413–420.

    Article  CAS  Google Scholar 

  18. Abdelkefi A, Ladeb S, Torjman L, Othman TB, Lakhal A, Romdhane NB et al. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood 2008; 111: 1805–1810.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bone Marrow and Stem Cell Transplant Program, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

    R L Olin, D T Vogl, D L Porter, S M Luger, S J Schuster, D E Tsai, D L Siegel, R J Cook, P A Mangan, K Cunningham & E A Stadtmauer

Authors
  1. R L Olin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D T Vogl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D L Porter
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S M Luger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S J Schuster
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D E Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D L Siegel
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R J Cook
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P A Mangan
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. K Cunningham
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. E A Stadtmauer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E A Stadtmauer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Olin, R., Vogl, D., Porter, D. et al. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant 43, 417–422 (2009). https://doi.org/10.1038/bmt.2008.334

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.334

Keywords

This article is cited by

Search

Advanced search

Quick links